

## **Supplemental information**

### **Exploring non-coding variants and evaluation of antisense oligonucleotides for splicing redirection in Usher syndrome**

**Belén García-Bohórquez, Pilar Barberán-Martínez, Elena Aller, Teresa Jaijo, Pablo Mínguez, Cristina Rodilla, Lidia Fernández-Caballero, Fiona Blanco-Kelly, Carmen Ayuso, Alba Sanchis-Juan, Sanne Broekman, Erik de Vrieze, Erwin van Wijk, Gema García-García, and José M. Millán**

**Table S1. Studies performed in the selected patients.**

Patient	Family	Gene	Dx	Allele 1	SS	NGS	SEG	Reference
<b>RP-331</b>	-	<b>USH2A</b>	<b>ARRP</b>	<b>c.2276G&gt;T; p.(Cys759Phe)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>1</sup>
RPN-645	FRPN-243	<i>USH2A</i> <i>CEP290</i>	ARRP	c.2276G>T; p.(Cys759Phe) c.7394_7395del; p.(Glu2465Valfs*2)	SP	P1	NA	<sup>1</sup> <sup>2</sup>
<b>RP-654</b>	<b>FRP-30</b>	<b>USH2A</b>	<b>USH</b>	<b>c.11146C&gt;T; p.(Gln3716*)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>3</sup>
RP-681	FRP-49	<i>CDH23</i>	USH	c.7279del; p.(Thr2427Leufs*47)	NP	P1	NA	<sup>4</sup>
RPN-803	FRPN-372	<i>USH2A</i> <i>ZNF408</i>	ARRP	c.2276G>T; p.(Cys759Phe) c.1534dup; p.(Arg512Profs*27)	NP	P1	NA	<sup>1</sup> This study
RP-903	FRP-57	<i>USH2A</i>	USH	c.5039A>G; p.(Lys1680Arg)	NP	P2	NA	<sup>5</sup>
RP-904	FRP-58	<i>USH2A</i>	USH	c.9799T>C; p.(Cys3267Arg)	SP	NP	NA	<sup>6</sup>
RP-925	-	<i>USH2A</i>	USH	c.2276G>T; p.(Cys759Phe)	SP	NP	NA	<sup>1</sup>
RP-963	FRP-140	<i>USH2A</i>	USH	c.2276G>T; p.(Cys759Phe)	SP	NP	NA	<sup>1</sup>
RP-1036	FRP-163	<i>USH2A</i>	USH	c.2809+1G>A; p.(?)	NP	P1	CC	<sup>7</sup>
RP-1222	FRP-228	<i>USH1C</i>	USH	c.1234G>A; p.(Asp412Asn)	NP	P1	NA	<sup>4</sup>
RP-1360	FRP-283	<i>USH2A</i>	USH	c.2276G>T; p.(Cys759Phe)	SP	P1	NA	<sup>1</sup>
RP-1387	FRP-320	<i>PCDH15</i>	USH	c.3817C>A; p.(Arg1273Ser)	NP	P1	NA	This study
RP-1455	FRP-337	<i>USH2A</i>	USH	c.5666A>G; p.(Asp1889Gly)	SP	P1	NA	<sup>8</sup>
<b>RP-1472</b>	<b>FRP-341</b>	<b>USH2A</b>	<b>USH</b>	<b>c.2299del; p.(Glu767Serfs*21)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>9</sup>
<b>RP-1485</b>	<b>FRP-344</b>	<b>USH2A</b>	<b>USH</b>	<b>c.1214del; p.(Asn405Ilefs*3)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>10</sup>
<b>RP-1494</b>	<b>FRP-348</b>	<b>USH2A</b>	<b>USH</b>	<b>c.2299del; p.(Glu767Serfs*21)</b>	<b>SP</b>	<b>NP</b>	<b>CC</b>	<sup>9</sup>
RP-1496	FRP-350	<i>ADGRV1</i>	USH	c.3443G>A; p.(Gly1148Asp)	NP	P1	NA	<sup>11</sup>
RP-1541	FRP-367	<i>USH2A</i>	USH	c.12067-2A>G; p.?	SP	NP	NA	<sup>12</sup>
<b>RP-1569</b>	<b>FRP-380</b>	<b>USH2A</b>	<b>USH</b>	<b>c.2299del; p.(Glu767Serfs*21)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>9</sup>
<b>RP-1595</b>	<b>FRP-389</b>	<b>USH2A</b>	<b>USH</b>	<b>c.10636G&gt;A; p.(Gly3546Arg)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>13</sup>
<b>RP-1596</b>				<b>c.10636G&gt;A; p.(Gly3546Arg)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	
RP-1600	FRP-391	<i>USH2A</i>	USH	c.1144G>A; p.(Gln5796*)	SP	P1	NA	<sup>13</sup>
RP-1634	FRP-410	<i>ADGRV1</i>	USH	c.17386C>T; p.(Gln5796*)	NP	P1	NA	<sup>14</sup>
RP-1635	FRP-411	<i>USH2A</i>	USH	c.2276G>T; p.(Cys759Phe)	SP	NP	NA	<sup>1</sup>
<b>RP-1647</b>	<b>FRP-417</b>	<b>USH2A</b>	<b>ARRP</b>	<b>c.2276G&gt;T; p.(Cys759Phe)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>1</sup>
RP-1716	FRP-437	<i>USH2A</i>	USH	c.5858C>G; p.(Ala1953Gly)	SP	P1	NA	<sup>15</sup>
RP-1726	FRP-448	<i>USH2A</i>	USH	c.13514A>G; p.(Tyr4505Cys)	SP	NP	NA	<sup>16</sup>
RP-1727	FRP-449	<i>USH2A</i>	USH	c.1214del; p.(Asn405Ilefs*3)	SP	NP	NA	<sup>10</sup>
RP-1728	FRP-446	<i>USH2A</i>	USH	c.13514A>G; p.(Tyr4505Cys)	SP	NP	NA	<sup>16</sup>
RP-1736	FRP-455	<i>USH2A</i>	USH	c.2299del; p.(Glu767Serfs*21)	SP	NP	NA	<sup>9</sup>
<b>RP-1741#</b>	<b>FRP-460</b>	<b>USH2A</b>	<b>USH</b>	<b>c.7595-2144A&gt;G; p.(Lys2532Thrfs*56)</b>	<b>SP</b>	<b>P1</b>	<b>NA</b>	<sup>3</sup>
<b>RP-1776</b>	<b>FRP-484</b>	<b>USH2A</b>	<b>ARRP + SNHL</b>	<b>c.2276G&gt;T; p.(Cys759Phe)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	<sup>1</sup>
RP-1815	FRP-505	<i>USH2A</i>	USH	c.908G>A; p.(Arg303His)	NP	P2	CC	<sup>17</sup>
RP-1943	FRP-566	<i>USH2A</i>	ARRP	c.2276G>T; p.(Cys759Phe)	SP	P1	NA	<sup>1</sup>
RP-1950	FRP-568	<i>USH2A</i>	USH	c.2299del; p.(Glu767Serfs*21)	SP	P1	NA	<sup>9</sup>
RP-1953	FRP-570	<i>USH1C</i>	USH	c.1859G>T; p.(Arg620Leu)	NP	P1	NA	<sup>18</sup>
RP-1994	FRP-585	<i>USH2A</i>	ARRP	c.2299del; p.(Glu767Serfs*21)	SP	P1	NA	<sup>9</sup>

RP-2034	FRP-614	<i>USH2A</i>	USH	c.2299del; p.(Glu767Serfs*21)	SP	P1	CC	9
<b>RP-2055</b>	<b>FRP-619</b>	<b><i>USH2A</i></b>	<b>USH</b>	<b>c.8435_8438del; p.(Thr2812Metfs*17)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	19
RP-2106	FRP-645	<i>USH2A</i>	USH	c.5933C>T; p.(Pro1978Leu)	SP	NP	NA	This study
RP-2131	FRP-667	<i>MYO7A</i>	USH	c.3G>A; p.(?)	NP	P1	NA	4
RP-2140	FRP-676	<i>CDH23</i>	USH	c.6393del; p.(Ile2132Serfs*11)	NP	P1	NA	20
RP-2159	FRP-675	<i>USH2A</i>	USH	c.3637_3642dup; p.(Phe1213_Alal214dup)	SP	P1	NA	This study
RP-2213	FRP-719	<i>MYO7A</i>	ARRP	c.640G>A; p.(Gly214Arg)	NP	P1	NA	21
RP-2214	FRP-720	<i>USH2A</i>	ARRP	c.2431_2432del; p.(Lys811Aspfs*11)	NP	P1	NA	6
<b>RP-2224</b>	<b>FRP-722</b>	<b><i>USH2A</i></b>	<b>USH</b>	<b>c.2431_2432del; p.(Lys811Aspfs*11)</b>	<b>SP</b>	<b>NP</b>	<b>NA</b>	6
RP-2232	FRP-722	<i>USH2A</i>	USH	c.1898C>A; p.(Ser633*)	SP	P1	NA	7
RP-2237	FRP-724	<i>USH2A</i>	ARRP	c.12575G>A; p.(Arg4192His)	SP	NP	NA	22
RP-2238	FRP-725	<i>USH2A</i> <i>PDE6H</i>	ARRP	c.1724G>A; p.(Cys575Tyr) c.134+2T>C; p.(?)	SP	NP	NA	23 This study
RP-2239	FRP-726	<i>USH2A</i>	ARRP	c.7061G>A; p.(Arg2354His)	SP	P1	NA	This study
RP-2241	FRP-728	<i>USH2A</i>	ARRP	c.2276G>T; p.(Cys759Phe)	SP	NP	NA	1
RP-2262	FRP-730	<i>ADGRV1</i>	USH	c.1875G>A; p.(Asp6252Asn)	NP	P1	NA	This study
RP-2264	FRP-732	<i>USH2A</i>	USH	c.1055C>T; p.(Thr352Ile)	SP	P2	NA	24
RP-2266	FRP-734	<i>USH2A</i>	USH	c.9799T>C; p.(Cys3267Arg)	SP	NP	NA	6
RP-2268	FRP-736	<i>USH2A</i>	ARRP	c.10073G>A; p.(Cys3358Tyr)	NP	P2	NA	15
RP-2269	FRP-737	<i>USH2A</i>	ARRP	c.1214del; p.(Asn405Ilefs*3)	NP	P2	NA	10
RP-2270	FRP-738	<i>USH2A</i>	ARRP	c.12574C>T; p.(Arg4192Cys)	NP	P2	NA	25
RP-2275	FRP-740	<i>USH2A</i>	USH	c.5776+1G>A; p.(?)	SP	P1	NA	26

Homozygous and heterozygous patients for deep-intronic variants in *USH2A* are highlighted in bold. RP/RPN: Patient number; "-": Unknown; RP/FRPN: Family number; Dx: Diagnosis; ARRP: Autosomal Recessive Retinitis Pigmentosa; USH: Usher Syndrome; SS: Sanger Screening; SP: Screening Performed; NP: Not Performed; P1: Panel design one; P2: Panel design two; SEG: Segregation analysis. The “#” symbol refers to the NGS positive control; CC: Cosegregation confirmed.

**Table S2. Sequence of antisense oligonucleotides tested for the aberrant splicing modulation caused by three deep-intronic variants.**

Variant	Oligonucleotide	Sequence (3'-5')	G-C%
<i>USH2A</i> : c.14134-3169A>G	AON1-PE64	CCAUUUUUCUAGGAGAAGCCC	47.6
	AON2-PE64	CAACUGUUUGUUCACAAGGU	40
<i>USH2A</i> : c.9958+3438A>G	AON1-PE50	UGCAGGUGUAAAAAUGGCCAAG	45.5
	AON7-PE50	UACCUUGACUGGAGUGAUCUC	47.6
<i>USH2A</i> : c.8681+3960A>G	AON1-PE43	CAGUGACAAUUUGGAUGGAGAC	45.5


G-C: Guanine-Cytosine content.

**Table S3. Primer sequences used for the minigene assays**

Variant	Restriction enzyme	Restriction site and tails	Primer sequence (5'-3')
<i>USH2A</i> : c.4106C>T	XhoI	AAGAATCTCGAG	gggaaatccagtacatcacc
	NheI	AAGAATGCTAGC	caatatcaactgagtgtggac
<i>USH2A</i> : c.5168-26A>C	XhoI	AAGAATCTCGAG	cactgcctctatatttacag
	NheI	AAGAATGCTAGC	catctgaaggagatggaac
<i>USH2A</i> : c.9958+3438A>G	XhoI	AAGAATCTCGAG	cctgtactatgactaaccag
	NheI	AAGAATGCTAGC	ggtgttctgacttctcttc
<i>USH2A</i> : c.8681+3960A>G	NdeI	AAGAATCATATG	gaagctgccgaagtgagtc
	NheI	AAGAATGCTAGC	gaacacgtgtcatggaactg


**RP-1036 (FRP-163)**

*USH2A*: c.2809+1G>A / **c.8681+3960A>G**




**RP-1494 (FRP-348)**

*USH2A*: **c.14134-3169A>G** / c.2299delG




**RP-2034 (FRP-614)**

*USH2A*: c.2299delG / **c.5168-26A>C**




**RP-1815 (FRP-505)**

*USH2A*: c.908G>A / **c.9958+3438A>G**



**Figure S1. Family pedigrees in which segregation analysis were assessed. Variants identified in this study are highlighted in bold.**



**Figure S2. Minigene constructs for the analysis of *USH2A* variants.** Regions inserted are depicted in blue in both sections A and B. In section A, constitutive exons are represented in yellow (SD6 and SA2). Each square in section B represents designs performed for each variant. PE: Pseudoexon; bp: base pair.

#### SUPPLEMENTAL REFERENCES

1. Dreyer, B., Tranebjærg, L., Rosenberg, T., Weston, M.D., Kimberling, W.J., and Nilssen, Ø. (2000). Identification of novel *USH2A* mutations: implications for the structure of *USH2A* protein. *Eur. J. Hum. Genet.* 8, 500–506. <https://doi.org/10.1038/sj.ejhg.5200491>.
2. Nishiguchi, K.M., and Rivolta, C. (2012). Genes Associated with Retinitis Pigmentosa and Allied Diseases Are Frequently Mutated in the General Population. *PLoS One* 7, e41902. <https://doi.org/10.1371/journal.pone.0041902>.
3. Vaché, C., Besnard, T., le Berre, P., García-García, G., Baux, D., Larrieu, L., Abadie, C., Blanchet, C., Bolz, H.J., Millan, J., et al. (2012). Usher syndrome type 2 caused by activation of an *USH2A* pseudoexon: Implications for diagnosis and therapy. *Hum. Mutat.* 33, 104–108. <https://doi.org/10.1002/humu.21634>.
4. Fuster-García, C., García-García, G., Jaijo, T., Fornés, N., Ayuso, C., Fernández-Burriel, M., Sánchez-De la Morena, A., Aller, E., and Millán, J.M. (2018). High-throughput

- sequencing for the molecular diagnosis of Usher syndrome reveals 42 novel mutations and consolidates CEP250 as Usher-like disease causative. *Sci. Rep.* 8, 17113. <https://doi.org/10.1038/s41598-018-35085-0>.
5. Costa, K.A., Salles, M.V., Whitebirch, C., Chiang, J., and Sallum, J.M.F. (2017). Gene panel sequencing in Brazilian patients with retinitis pigmentosa. *Int. J. Retin. Vitre.* 3, 33. <https://doi.org/10.1186/s40942-017-0087-6>.
  6. Nájera, C., Beneyto, M., Blanca, J., Aller, E., Fontcuberta, A., Millán, J.M., and Ayuso, C. (2002). Mutations in Myosin VIIA ( MYO7A ) and Usherin ( USH2A ) in Spanish patients with usher syndrome types I and II, respectively. *Hum. Mutat.* 20, 76–77. <https://doi.org/10.1002/humu.9042>.
  7. Baux, D., Blanchet, C., Hamel, C., Meunier, I., Larrieu, L., Faugère, V., Vaché, C., Castorina, P., Puech, B., Bonneau, D., et al. (2014). Enrichment of LOVD-USHbases with 152 USH2A Genotypes Defines an Extensive Mutational Spectrum and Highlights Missense Hotspots. *Hum. Mutat.* 35, 1179–1186. <https://doi.org/10.1002/humu.22608>.
  8. Perea-Romero, I., Gordo, G., Iancu, I.F., Del Pozo-Valero, M., Almoguera, B., Blanco-Kelly, F., Carreño, E., Jimenez-Rolando, B., Lopez-Rodriguez, R., Lorda-Sanchez, I., et al. (2021). Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications. *Sci. Rep.* 11, 1526. <https://doi.org/10.1038/s41598-021-81093-y>.
  9. Eudy, J.D., Weston, M.D., Yao, S., Hoover, D.M., Rehm, H.L., Ma-Edmonds, M., Yan, D., Ahmad, I., Cheng, J.J., Ayuso, C., et al. (1998). Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. *Science* 280, 1753–1757.
  10. Bernal, S., Medà, C., Solans, T., Ayuso, C., Garcia-Sandoval, B., Valverde, D., Del Rio, E., and Baiget, M. (2005). Clinical and genetic studies in Spanish patients with Usher syndrome type II: description of new mutations and evidence for a lack of genotype-

- phenotype correlation. *Clin. Genet.* 68, 204–214. <https://doi.org/10.1111/j.1399-0004.2005.00481.x>.
11. Wang, J., Zhang, V.W., Feng, Y., Tian, X., Li, F.Y., Truong, C., Wang, G., Chiang, P.W., Lewis, R.A., and Wong, L.J.C. (2014). Dependable and efficient clinical utility of target capture-based deep sequencing in molecular diagnosis of retinitis pigmentosa. *Investig. Ophthalmol. Vis. Sci.* 55, 6213–6223. <https://doi.org/10.1167/iovs.14-14936>.
  12. Rivolta, C., Sweklo, E.A., Berson, E.L., and Dryja, T.P. (2000). Report Missense Mutation in the USH2A Gene: Association with Recessive Retinitis Pigmentosa without Hearing Loss. *Am. J. Hum. Genet* 66, 1975–1978. <https://doi.org/10.1086/302926>.
  13. Garcia-Garcia, G., Aparisi, M.J., Jaijo, T., Rodrigo, R., Leon, A.M., Avila-fernandez, A., Blanco-kelly, F., Bernal, S., Navarro, R., Diaz-llopis, M., et al. (2011). Mutational screening of the USH2A gene in Spanish USH patients reveals 23 novel pathogenic mutations. 1–13.
  14. García-García, G., Besnard, T., Baux, D., Vaché, C., Aller, E., Malcolm, S., Claustres, M., Millan, J.M., and Roux, A.-F. (2013). The contribution of GPR98 and DFNB31 genes to a Spanish Usher syndrome type 2 cohort. *Mol. Vis.* 19, 367–373.
  15. McGee, T.L., Seyedahmadi, B.J., Sweeney, M.O., Dryja, T.P., and Berson, E.L. (2010). Novel mutations in the long isoform of the USH2A gene in patients with Usher syndrome type II or non-syndromic retinitis pigmentosa. *J. Med. Genet.* 47, 499–506. <https://doi.org/10.1136/jmg.2009.075143>.
  16. Zampaglione, E., Kinde, B., Place, E.M., Navarro-Gomez, D., Maher, M., Jamshidi, F., Nassiri, S., Mazzone, J.A., Finn, C., Schlegel, D., et al. (2020). Copy-number variation contributes 9% of pathogenicity in the inherited retinal degenerations. *Genet. Med.* 22, 1079–1087. <https://doi.org/10.1038/s41436-020-0759-8>.
  17. Yan, D., Ouyang, X., Patterson, D.M., Du, L.L., Jacobson, S.G., and Liu, X.-Z. (2009).

- Mutation analysis in the long isoform of USH2A in American patients with Usher Syndrome type II. *J. Hum. Genet.* 54, 732–738. <https://doi.org/10.1038/jhg.2009.107>.
18. Bonnet, C., Riahi, Z., Chantot-bastaraud, S., Smagghe, L., Letexier, M., Marcaillou, C., Lefèvre, G.M., Hardelin, J., El-amraoui, A., Singh-estivalet, A., et al. (2016). An innovative strategy for the molecular diagnosis of Usher syndrome identifies causal biallelic mutations in 93 % of European patients. 1730–1738. <https://doi.org/10.1038/ejhg.2016.99>.
  19. Aller, E., Jaijo, T., Beneyto, M., Na, C., Oltra, S., Ayuso, C., Baiget, M., Carballo, M., Antin, G., Navea, A., et al. (2006). Identification of 14 novel mutations in the long isoform of. 1–5. <https://doi.org/10.1136/jmg.2006.041764>.
  20. Oshima, A., Jaijo, T., Aller, E., Millan, J.M., Carney, C., Usami, S., Moller, C., and Kimberling, W.J. (2008). Mutation profile of the CDH23 gene in 56 probands with Usher syndrome type I. *Hum. Mutat.* 29, E37–E46. <https://doi.org/10.1002/humu.20761>.
  21. Adato, A., Weiv, D., Kalinski, H., Ayadi, H., Petit, C., and Korostishevsky, M. (1997). Mutation Profile of All 49 Exons of the Human Myosin VIIA Gene , and Haplotype Analysis , in Usher 1 B Families from Diverse Origins. 813–821.
  22. Ávila-Fernández, A., Cantalapiedra, D., Aller, E., Vallespín, E., Aguirre-Lambán, J., Blanco-Kelly, F., Corton, M., Riveiro-Álvarez, R., Allikmets, R., Trujillo-Tiebas, M.J., et al. (2010). Mutation analysis of 272 Spanish families affected by autosomal recessive retinitis pigmentosa using a genotyping microarray. *Mol. Vis.* 16, 2550–2558. <https://doi.org/272> [pii].
  23. Bonnet, C., Grati, M., Marlin, S., Levilliers, J., Hardelin, J.P., Parodi, M., Niasme-Grare, M., Zelenika, D., Délépine, M., Feldmann, D., et al. (2011). Complete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis. *Orphanet J. Rare Dis.* 6, 21. <https://doi.org/10.1186/1750-1172-6-21>.



24. Baux, D., Larrieu, L., Blanchet, C., Hamel, C., Ben Salah, S., Vielle, A., Gilbert-Dussardier, B., Holder, M., Calvas, P., Philip, N., et al. (2007). Molecular and in silico analyses of the full-length isoform of usherin identify new pathogenic alleles in Usher type II patients. *Hum. Mutat.* 28, 781–789. <https://doi.org/10.1002/humu.20513>.
25. Corton, M., Tatu, S.D., Avila-Fernandez, A., Vallespín, E., Tapias, I., Cantalapiedra, D., Blanco-Kelly, F., Riveiro-Alvarez, R., Bernal, S., García-Sandoval, B., et al. (2013). High frequency of CRB1 mutations as cause of Early-Onset Retinal Dystrophies in the Spanish population. *Orphanet J. Rare Dis.* 8. <https://doi.org/10.1186/1750-1172-8-20>.
26. Sandberg, M.A., Rosner, B., Weigel-DiFranco, C., McGee, T.L., Dryja, T.P., and Berson, E.L. (2008). Disease Course in Patients with Autosomal Recessive Retinitis Pigmentosa due to the USH2A Gene. *Investig. Ophthalmology Vis. Sci.* 49, 5532. <https://doi.org/10.1167/iovs.08-2009>.